TMEM236: A Potential Drug Target and Biomarker (G653567)

Target Name: TMEM236

NCBI ID: G653567

TMEM236: A Potential Drug Target and Biomarker

TMEM236, a member of the transmembrane protein family 23 (TMEM23), is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TMEM236 is a 21-kDa protein that is expressed in most tissues and cells in the body. It is characterized by a transmembrane domain and a cytoplasmic tail that is involved in its stability and localization to various cell types.

The TMEM236 gene was first identified in 2004 and has since been extensively studied to determine its function and potential as a drug target. Several studies have shown that TMEM236 is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival. It is also known to be involved in the regulation of ion channels, which are critical for the flow of electrical current through the cell membrane.

One of the key features of TMEM236 is its potential druggability. TMEM236 has been shown to have a unique expression pattern in various tissues and cells, which makes it an attractive target for small molecules. In addition, the cytoplasmic tail of TMEM236 provides a surface for various signaling molecules, making it more vulnerable to drug-like molecules.

TMEM236 has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that TMEM236 is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also has been shown to be involved in the regulation of immune cell function, which may contribute to the development of autoimmune disorders.

In addition to its potential role in disease, TMEM236 has also been shown to be a potential biomarker. Studies have shown that TMEM236 can be used as a protein biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The ability to use TMEM236 as a biomarker makes it an attractive target for drug development, as it allows for the early detection and diagnosis of disease.

TMEM236 has also been shown to be involved in the regulation of cellular signaling pathways. Studies have shown that TMEM236 is involved in the regulation of several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These signaling pathways are important for various cellular processes, including cell growth, cell adhesion, and cell survival.

In conclusion, TMEM236 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique expression pattern and drug-like properties make it an attractive target for small molecules. Further studies are needed to determine its role in disease and to develop effective biomarkers for its use.

Protein Name: Transmembrane Protein 236

More Common Targets